Beyond the Trial: Real-World Evidence for Bispecific Antibodies Across a Broad RRFL Population

In this episode, 'Beyond the Trial: Real-World Evidence for Bispecific Antibodies Across a Broad RRFL Population,' Christina Poh, MD explores the following questions:

Real-world data on mosunetuzumab and epcoritamab use from eight CUBIC centers shows response rates that exceed or match what was seen in the pivotal trials, in a heavily pretreated and older population. How do you interpret that, and what does it tell you about how well the trial populations for these agents reflected the patients treated in practice?

One intriguing finding was that response rates and PFS were not significantly influenced by prior CAR-T exposure, FLIPI score, elevated LDH, or ECOG performance status. How does that influence your thinking about which RRFL patients you would and would not consider appropriate candidates for bispecific antibody therapy?

Christina Poh described the real-world data from eight CUBIC centers as highly encouraging, interpreting response rates that match or exceed those seen in pivotal trials in a heavily pretreated and older patient population as confirmation that bispecific antibodies are a broadly active and impressive class of treatment that already plays an important role in relapsed or refractory follicular lymphoma. She also noted that the finding that response rates and PFS were not significantly influenced by prior CAR-T exposure, FLIPI score, elevated LDH, or ECOG performance status suggests that bispecific antibodies are broadly effective across a wide range of patients regardless of baseline disease characteristics, shifting the conversation around patient selection away from disease biology and toward factors such as patient preference and practical access, since these therapies are currently administered primarily at academic centers and may not be readily accessible to patients who cannot or are unwilling to travel significant distances for treatment.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'The Future of RRFL: Personalized Treatment, Novel Agents, and Moving Beyond Chemotherapy,' features Christina Poh sharing her closing reflections on the evolving relapsed or refractory follicular lymphoma treatment landscape — highlighting the shift away from conventional chemotherapy toward highly effective, personalized treatment approaches tailored to patient and disease-specific characteristics, and her overall optimism about what the near future holds for this patient population.